Hypertrophic scars in a patient with Turner's syndrome treated with recombinant growth hormone
نویسندگان
چکیده
Turner's syndrome is a common genetic disorder of girls and women, for which characteristic clinical symptoms encompass short stature, gonadal dysgenesis, systemic defects, multiple dysmorphic features and skin changes, including an increased number of melanocytic nevi, hypertrophic scars and keloids. The affected girls are treated with recombinant human growth hormone to improve the height. We present a case of a 15-year-old girl with Turner's syndrome, hypertrophic scars and a keloid. At the age of 12 years and 8 months, the girl started recombinant human growth hormone treatment. During the therapy, a surgical excision of 4 out of 42 benign melanocytic nevi was performed. After 2 months the hypertrophic scars as well as a keloid were noted at sites of excision. Parents of girls with Turner's syndrome undertake various attempts to improve not only the height and maturity of their daughters, but also their appearance by commonly performed surgical corrections of the webbed neck and pigmented nevi. The presented case suggests an increased risk of scars hypertrophy and keloid formations after surgical intervention in Turner's syndrome patients who are treated with recombinant human growth hormone at the same time. Due to that it should be advised to postpone all planned surgical procedures until the therapy has been completed.
منابع مشابه
EFFEC T OF HUMAN GROWTH HORMONE TREATMEN T IN CHILDREN WI TH GROWTH HORMONE DEFICIENCY, TURNER\'S SYNDROME AND ACHONDROPLASIA: A COMPARISON OF DOSE FREQUENCY AND ROU TE OF ADMINIS1RATION
Recombinant human growth hormone (hGH) was given for 6 months or longer to 68 patients with GH deficiency, 6 with Turner's syndrome and 5 with achondroplasia, during 1986-1994 in a prospective study. The total weekly administered dose of GH was 0.6 u/kg. By random sampling, 29 of 68 GH deficient patients (42.6%) received twice weekly (2 iw) intramuscular (im) injections, 17 (25%) received ...
متن کاملPapillary Carcinoma of Thyroid Gland in a Patient Treated with Recombinant Growth Hormone
The first successful treatment of growth hormone (GH) deficient children with GH extracted from human pituitary was introduced during late 1950's. The subsequent availability and use of recombinant GH (rhGH) for different clinical conditions raised the question of whether this new therapeutic modality increases the risk of certain conditions such as leukemia or malignancy. Herein, we report o...
متن کاملسندرم نونان (گزارش یک مورد)
Noonan syndrome is a genetic condition inherited by an autosomally dominant manner, characterised by congenital heart disease, short stature, abnormal facies and the somatic feature of Turner's syndrome, but a normal karyotype. Noonan syndrome affects approximately 1 in 1500 live births. Congenital heart disease occurs in 35-50% of patients diagnosed with noonan syndrome. The most common cardia...
متن کاملRecombinant growth hormone therapy in a girl with costello syndrome: a 4-year observation
BACKGROUND Costello syndrome is a rare syndrome of multiple congenital anomalies. The typical clinical traits include dysmorphic craniofacial features, skin hyperpigmentation and excess, feeding difficulties leading to severe postnatal growth retardation, short stature, joint hypermobility, and delayed psychomotor development. Additionally, Costello syndrome may present with an increased incide...
متن کاملEffect of obesity on endogenous secretion of growth hormone in Turner's syndrome.
Nocturnal growth hormone secretion over a 12 hour period was assessed at 20 minute intervals in 25 prepubertal subjects with Turner's syndrome and 11 normal prepubertal girls of short stature to try and elucidate the relationship between body weight and endogenous secretion of growth hormone in Turner's syndrome. There were no differences in mean growth hormone concentration, age, height, or gr...
متن کامل